Navigation Links
EuroPharma Exclusive Distributor of BCM-95 and BosPure
Date:12/16/2009

GREEN BAY, Wis., Dec. 16 /PRNewswire/ -- EuroPharma, Inc. signs exclusive multi-year contract with DolCas Biotech for the use of super absorbency BCM-95® curcumin and specialized BosPure® boswellia in multiple EuroPharma formulations. The exclusive distribution territory for these clinically-studied ingredients includes both the health food store channel and professional channel, which includes allopathic doctors, chiropractors, naturopathic doctors, and clinics. BCM-95® is a highly absorbable curcumin. Human clinical data indicates that BCM-95 is up to 10 times more absorbable than curcumin 95% and 6.3 times more absorbable than curcumin with lecithin and piperine. BosPure® boswellia is beta-boswellic acid free, and standardized to contain 10-15% AKBA (Acetyl-11-Keto-Beta-Boswellic Acid), which enhances its targeted impact on the body's natural anti-inflammatory response.

Currently, EuroPharma distributes unique formulations that contain a combination of BCM-95 and BosPure: Curamin®, Curacel(TM), Dyflaminol(TM) and Bos-Cur(TM). EuroPharma also distributes an all-curcumin product, CuraMed(TM), containing 750 mgs of BCM-95 phospholipid complex, which is equivalent to up to 7,500 mgs of curcumin 95%. Due to consumer demand, they have also created a softgel containing 375 mg dose (equivalent to up to 3,700 mgs of curcumin 95%).

Curamin has rapidly become the number one pain* relieving formula in America, and has won the 2009 VityAward as best new supplement on the market, and both the 2008 and 2009 Best of Supplements awards.

Dyflaminol is recommended for support of a healthy anti-inflammatory response. Bos-Cur is indicated for balancing healthy leukotrienes, which are signaling substances intimately involved in a healthy inflammatory response. Curacel, which also contains resveratrol and green tea polyphenols, is recommended for healthy cellular function, particularly for breast, pro
'/>"/>

SOURCE EuroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
3. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
4. Health Robotics Reaches 100% Asia-Pacific Coverage Through its New Exclusive Distribution Contract With BioRobotics in Korea
5. Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
6. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
7. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... With the NCAA set to undergo ... an interview with Yale University Associate Athletic Director Steve ... approach to ensuring student-athlete experience that is consistent with ... a number of key factors that contribute to a ... factor in creating this culture seems simple at first. ...
(Date:8/31/2014)... tea reduces non-cardiovascular mortality by 24%, reveals a study ... by Professor Nicolas Danchin from France. , Professor Danchin ... coffee it,s probably better to drink tea. Coffee and ... Their effects on cardiovascular (CV) health have been investigated ... the effects of coffee and tea on CV mortality ...
(Date:8/30/2014)... Barcelona, Spain Sunday 31 August 2014: A ... and safe in a real world setting, according ... by Dr Stylianos Pyxaras from Germany. The direct ... features that improve operator control and has the ... outcomes in patients with severe aortic stenosis. , ...
(Date:8/30/2014)... 31, 2014 Not only is USHEALTH Advisors ... has just recorded its highest level of late-summer sales, including ... company is going to set a new record in 2014,” ... “Our growth in both weekly annualized volume and the ... last week of August, we saw even more of our ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, ... a best-seller within golf and tennis. Golfers and tennis players ... most by using the compression elbow sleeve to help treat ... condition that causes pain on the inner side of your ... the bony bump on the inside of your elbow. The ...
Breaking Medicine News(10 mins):Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2
... are less likely to develop high blood pressure say researchers ... the study researchers analyzed data from two large studies, which ... women questionnaires, which asked about their folate and supplemental folic ... at the start of the study. It was found that ...
... suggest people who carry a gene that produces a ... small increased risk for stroke.// ,Researchers reviewed medical ... found that previous study results were observational in nature. ... confounding factors by looking at data on the link ...
... a recent study researchers have linked breathing cancer-causing compounds ... cancer among offspring. They also believe that nearly all ... mother’s inhalation of noxious substances. ,The study compared ... and younger who died from leukemia and other cancers ...
... Men who receive a common therapy after prostate cancer surgery ... based on // findings of a recent study. For ... therapy suffered a broken bone within five years of diagnosis, ... receive the treatment. ,Androgen-deprivation therapy has traditionally been given ...
... Several studies have linked the use of estrogen replacement therapy ... mineral density( BMD ) is known as a good indicator ... men to determine how BMD related to the risk of ... decline at the beginning of the study. Researchers then measured ...
... Previous studies have shown inhaled corticosteroids can reduce the ... However, results from a study conducted by researchers from ... more than 2,650 patients with COPD who were prescribed ... 90-day period. Nearly 5,400 patients who had never used ...
Cached Medicine News:
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Red Lens Maddox...
Maddox Rod, short handle (12cm)...
Medicine Products: